ash 2022: talquetamab showing promise in multiple myeloma clinical trial
Published 1 year ago • 462 plays • Length 4:57Download video MP4
Download video MP3
Similar videos
-
3:44
ash 2021: new bispecific antibody, talquetamab, to treat multiple myeloma
-
10:02
ash 2022: talquetamab in patients with relapsed/refractory multiple myeloma (rrmm): phase 1/2 re...
-
2:03
natural killer cells as add-on therapy for multiple myeloma is showing promise in the lab
-
1:00
highlights at ash 2022: the promise of t-cell redirecting therapies in multiple myeloma
-
5:29
updates on teclistamab, talquetamab, and carvykti | mark wildgust, phd | ash 2022
-
9:33
talquetamab | ajai chari, md | ash 2022
-
6:10
updated phase1b results for talquetamab in combination with daratumumab
-
2:28
modakafusp alfa shows promise in treating multiple myeloma, study finds
-
0:50
recent updates from the promise study
-
2:41
monumental-1: talquetamab for multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:21
next steps for the trimm-2 study of combination therapies for multiple myeloma
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
10:11
monumental-1: talquetamab in r/r multiple myeloma
-
2:27
addressing the disparity in ethnic variation in uk-based clinical trials for multiple myeloma
-
2:04
ash 2018: earlier smoldering myeloma treatment & the promise study
-
3:59
multiple myeloma highlights from ash 2020
-
1:12:04
multiple myeloma: a post-ash22 summary
-
6:02
talquetamab: robust efficacy and manageable safety for heavily pretreated r/r multiple myeloma